AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37936657 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchful Waiting (WW)
Number of subjects: 496
Study 33402259 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (10-week treatment)
Number of subjects: 78
Study 33402259 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (12-week treatment)
Number of subjects: 78
Study 33402259 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for both trials)
Number of subjects: 78
Study 35303890 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed patient-specific instrument (PSI) based on H-point
Number of subjects: 26
Study 35303890 — intervention group
Group type: COMPARATOR
Intervention: Control group with standard technique
Number of subjects: 26
Study 32429355 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced protein distribution
Number of subjects: 0
Study 32429355 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufficient protein quantity in at least one meal
Number of subjects: 0
Study 34122679 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent of visceral pleural invasion (VPI) incorporated into a prognostic nomogram
Number of subjects: 87045
Study 34122679 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (n=60,933)
Number of subjects: 87045
Study 34122679 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation group (n=26,112)
Number of subjects: 87045
Study 34122679 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration curve assessment
Number of subjects: 87045
Study 36342382 — intervention group
Group type: EXPERIMENTAL
Intervention: Online educational course for medical providers
Number of subjects: 0
Study 36342382 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 36342382 — intervention group
Group type: EXPERIMENTAL
Intervention: Online educational course
Number of subjects: 0
Study 36342382 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical and nursing trained intervention group
Number of subjects: 0
Study 36342382 — intervention group
Group type: COMPARATOR
Intervention: Medical and nursing trained control group
Number of subjects: 0
Study 33285282 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% alcoholic chlorhexidine
Number of subjects: 113
Study 33285282 — intervention group
Group type: COMPARATOR
Intervention: 5% alcoholic povidone-iodine
Number of subjects: 113
Study 34663704 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal ctDCS
Number of subjects: 60
Study 34663704 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal ctDCS
Number of subjects: 60
Study 34663704 — intervention group
Group type: COMPARATOR
Intervention: Sham ctDCS
Number of subjects: 60
Study 32855633 — intervention group
Group type: EXPERIMENTAL
Intervention: 140 Hz tACS
Number of subjects: 43
Study 32855633 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Hz tACS
Number of subjects: 43
Study 32855633 — intervention group
Group type: EXPERIMENTAL
Intervention: tRNS
Number of subjects: 43
Study 32855633 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (1 mA)
Number of subjects: 43
Study 34725453 — intervention group
Group type: EXPERIMENTAL
Intervention: AYA patients (16-30 years)
Number of subjects: 597
Study 34725453 — intervention group
Group type: COMPARATOR
Intervention: Younger patients (1-15 years)
Number of subjects: 597
Study 33783568 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic containers
Number of subjects: 43
Study 33783568 — intervention group
Group type: COMPARATOR
Intervention: Glass containers
Number of subjects: 43
Study 33673788 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT) consisting of supervised bicep curls 3 days per week for 4 weeks (5 sets of 10 repetitions at 75% of 1-repetition maximum)
Number of subjects: 36
Study 33673788 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=15)
Number of subjects: 36
Study 32846775 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Therapy Exercises (PTE)
Number of subjects: 60
Study 32846775 — intervention group
Group type: EXPERIMENTAL
Intervention: Wharton Jelly mesenchymal stem cell (WJ‐MSCs) injections
Number of subjects: 60
Study 32846775 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (PTE + WJ‐MSCs)
Number of subjects: 60
Study 36092975 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 7
Study 36092975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 32203712 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab (15 mg/kg, intramuscular injections during RSV season)
Number of subjects: 429
Study 32203712 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 429
Study 32203712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study 32203712 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of PCR-confirmed RSV infection at 1 year
Number of subjects: 429
Study 32203712 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversible airway obstruction at 6 years
Number of subjects: 429
Study 35803628 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase progesterone for 3 weeks
Number of subjects: 1800
Study 35803628 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase progesterone for 7 weeks
Number of subjects: 1800
Study 35803628 — intervention group
Group type: COMPARATOR
Intervention: No luteal phase progesterone
Number of subjects: 1800
Study 36370176 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen peptides (CP) 10 g·day‐1
Number of subjects: 20
Study 36370176 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (CON)
Number of subjects: 20
Study 33470341 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg codeine and 500 mg acetaminophen (4 times a day for 4 days)
Number of subjects: 40
Study 33470341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 32717180 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-look surgery plus oxaliplatin-HIPEC (oxaliplatin 460 mg/m2, or oxaliplatin 300 mg/m2 plus irinotecan 200 mg/m2, plus intravenous fluorouracil 400 mg/m2)
Number of subjects: 150
Study 32717180 — intervention group
Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 150
Study 35367245 — intervention group
Group type: EXPERIMENTAL
Intervention: STRIP intervention group (heart-healthy diet with low SAFAs and cholesterol, counseling at least biannually from age 7 months to 20 years)
Number of subjects: 0
Study 35367245 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study 34584543 — intervention group
Group type: EXPERIMENTAL
Intervention: MIXTIVA infusion (remifentanil/propofol at a proportion of 2/1,000 or 3/1,000)
Number of subjects: 96
Study 34584543 — intervention group
Group type: COMPARATOR
Intervention: Standard TIVA with separate remifentanil and propofol infusions (Control Group I)
Number of subjects: 96
Study 34584543 — intervention group
Group type: EXPERIMENTAL
Intervention: MIXTIVA infusion (Group III with remifentanil concentration 30 µg/ml)
Number of subjects: 96
Study 34584543 — intervention group
Group type: EXPERIMENTAL
Intervention: MIXTIVA infusion (Group II with remifentanil concentration 20 µg/ml)
Number of subjects: 96
Study 34084153 — intervention group
Group type: EXPERIMENTAL
Intervention: CDCA 1.25 g
Number of subjects: 20
Study 34084153 — intervention group
Group type: COMPARATOR
Intervention: CDCA 1.25 g + colesevelam 3.75 g
Number of subjects: 20
Study 34084153 — intervention group
Group type: EXPERIMENTAL
Intervention: CDCA 1.25 g (with mixed meal)
Number of subjects: 20
Study 34084153 — intervention group
Group type: EXPERIMENTAL
Intervention: colesevelam 3.75 g (with mixed meal)
Number of subjects: 20
Study 34084153 — intervention group
Group type: EXPERIMENTAL
Intervention: colesevelam 3.75 g × 2 (with mixed meal)
Number of subjects: 20
Study 34084153 — intervention group
Group type: COMPARATOR
Intervention: No additions (with mixed meal)
Number of subjects: 20
Study 32308366 — intervention group
Group type: EXPERIMENTAL
Intervention: N-butylphthalide (NBP) and dexamethasone (DXM) combined with hyperbaric oxygen (HBO) therapy
Number of subjects: 171
Study 32308366 — intervention group
Group type: COMPARATOR
Intervention: HBO therapy as monotherapy (Control)
Number of subjects: 171
Study 32197629 — intervention group
Group type: EXPERIMENTAL
Intervention: NEMEX-TJR twice weekly for 12 weeks combined with two sessions of PNE
Number of subjects: 120
Study 32197629 — intervention group
Group type: COMPARATOR
Intervention: Two sessions of PNE given over 6 weeks
Number of subjects: 120
Study 32197629 — intervention group
Group type: EXPERIMENTAL
Intervention: NEMEX-TJR and PNE
Number of subjects: 120
Study 34649935 — intervention group
Group type: EXPERIMENTAL
Intervention: IV alteplase prior to MT
Number of subjects: 235
Study 34649935 — intervention group
Group type: COMPARATOR
Intervention: MT-only group (no alteplase)
Number of subjects: 235
Study 34649935 — intervention group
Group type: EXPERIMENTAL
Intervention: IV alteplase + aspiration first MT
Number of subjects: 235
Study 34649935 — intervention group
Group type: COMPARATOR
Intervention: No alteplase + aspiration first MT
Number of subjects: 235
Study 34649935 — intervention group
Group type: EXPERIMENTAL
Intervention: IV alteplase + stent retriever first MT
Number of subjects: 235
Study 34649935 — intervention group
Group type: COMPARATOR
Intervention: No alteplase + stent retriever first MT
Number of subjects: 235
Study 33314283 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 116
Study 33314283 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 116
Study 35598187 — intervention group
Group type: EXPERIMENTAL
Intervention: Soap cleaning
Number of subjects: 100
Study 35598187 — intervention group
Group type: EXPERIMENTAL
Intervention: Soap-plus-microwave
Number of subjects: 100
Study 33549019 — intervention group
Group type: EXPERIMENTAL
Intervention: PSORI-CM01 granules
Number of subjects: 63
Study 33549019 — intervention group
Group type: COMPARATOR
Intervention: Yinxieling tablets
Number of subjects: 63
Study 32229324 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (250 mg)
Number of subjects: 33
Study 32229324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 32808147 — intervention group
Group type: EXPERIMENTAL
Intervention: HILT plus therapeutic exercises
Number of subjects: 36
Study 32808147 — intervention group
Group type: COMPARATOR
Intervention: Sham-laser plus therapeutic exercises
Number of subjects: 36
Study 32808147 — intervention group
Group type: COMPARATOR
Intervention: Control-therapeutic exercises only
Number of subjects: 36
Study 36028894 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital aftercare service
Number of subjects: 150
Study 36028894 — intervention group
Group type: COMPARATOR
Intervention: Regular aftercare (TAU)
Number of subjects: 150
Study 36470906 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation breathing
Number of subjects: 147
Study 36470906 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation breathing combined with cardiac biofeedback
Number of subjects: 147
Study 36470906 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 147
Study 33389761 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano-curcumin (Sinacurcumin soft gel, 40 mg curcuminoids as nanomicelles, two capsules twice a day)
Number of subjects: 41
Study 33389761 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 41
Study 35938937 — intervention group
Group type: EXPERIMENTAL
Intervention: Extract of Dolichos biflorus seeds (1,600 mg)
Number of subjects: 96
Study 35938937 — intervention group
Group type: EXPERIMENTAL
Intervention: Extract of Cynodon dactylon rhizome (1,600 mg)
Number of subjects: 96
Study 35938937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 34362522 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin (ASTA) at concentrations of 5, 10, and 20 μmol/L
Number of subjects: 0
Study 34362522 — intervention group
Group type: COMPARATOR
Intervention: Control group A (DMSO added)
Number of subjects: 0
Study 32902210 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta check limits for outpatients
Number of subjects: 434927
Study 32902210 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta check limits for inpatients
Number of subjects: 434927
Study 32902210 — intervention group
Group type: COMPARATOR
Intervention: Reference change value (RCV)
Number of subjects: 434927
Study 32902210 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta check procedure
Number of subjects: 434927
Study 36178031 — intervention group
Group type: EXPERIMENTAL
Intervention: Videos
Number of subjects: 320
Study 36178031 — intervention group
Group type: EXPERIMENTAL
Intervention: Podcasts
Number of subjects: 320
Study 36178031 — intervention group
Group type: EXPERIMENTAL
Intervention: Texts
Number of subjects: 320
Study 32239171 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced blood-stage malaria (IBSM)
Number of subjects: 24
Study 32239171 — intervention group
Group type: COMPARATOR
Intervention: Mosquito bite (MB)
Number of subjects: 24
Study 32452912 — intervention group
Group type: EXPERIMENTAL
Intervention: Unadjusted approach assuming data are missing-completely-at-random (MCAR)
Number of subjects: 100000
Study 32452912 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratification on baseline predictors
Number of subjects: 100000
Study 32452912 — intervention group
Group type: EXPERIMENTAL
Intervention: Full adjustment for baseline and time-updated variables
Number of subjects: 100000
Study 36126565 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 275
Study 36126565 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor
Number of subjects: 275
Study 36126565 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (discontinued <3 days before surgery)
Number of subjects: 275
Study 36126565 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (discontinued ≥3 days)
Number of subjects: 275
Study 36126565 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (discontinued <3 days before surgery)
Number of subjects: 275
Study 36126565 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (discontinued ≥3 days)
Number of subjects: 275
Study 33873075 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiasp®
Number of subjects: 67
Study 33873075 — intervention group
Group type: COMPARATOR
Intervention: NovoLog®
Number of subjects: 67
Study 32776103 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg methylphenidate
Number of subjects: 48
Study 32776103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 36498603 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D adjustable posture corrective orthotic (PCO) added to a multimodal program; performed mirror image therapy for 20–30 min while walking on a treadmill 2–3 times per week for 10 weeks.
Number of subjects: 24
Study 36498603 — intervention group
Group type: COMPARATOR
Intervention: Multimodal program without the 3D PCO.
Number of subjects: 24
Study 32658939 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IR, n = 40) wore face shields and hand sanitized frequently
Number of subjects: 52
Study 32658939 — intervention group
Group type: COMPARATOR
Intervention: Control group (CR, n = 35)
Number of subjects: 52
Study 32950989 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal device (soft silicone insert) for 5-12 hours daily
Number of subjects: 156
Study 32950989 — intervention group
Group type: COMPARATOR
Intervention: Normal saline drops (control group)
Number of subjects: 156
Study 32248698 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive web training (IWT)
Number of subjects: 0
Study 32248698 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study 33213471 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmodium vivax infection
Number of subjects: 4200
Study 33213471 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum infection
Number of subjects: 4200
Study 33213471 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent travels to forest sites
Number of subjects: 4200
Study 33213471 — intervention group
Group type: EXPERIMENTAL
Intervention: Forest work
Number of subjects: 4200
Study 33213471 — intervention group
Group type: EXPERIMENTAL
Intervention: Residing in villages at the forest fringe or inside the forest
Number of subjects: 4200
Study 33213471 — intervention group
Group type: EXPERIMENTAL
Intervention: Village-level differences in prevalence
Number of subjects: 4200
Study 33213471 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial hotspots of infection in villages inside the forest
Number of subjects: 4200
Study 34021326 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical cognitive simulation (SCS) training
Number of subjects: 21
Study 34021326 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SCS training)
Number of subjects: 21
Study 36289500 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS bone graft delivery device
Number of subjects: 73
Study 36289500 — intervention group
Group type: COMPARATOR
Intervention: Conventional system
Number of subjects: 73
Study 34714112 — intervention group
Group type: EXPERIMENTAL
Intervention: PRC-063 (all doses combined; 25, 45, 70, or 85 mg/day)
Number of subjects: 367
Study 34714112 — intervention group
Group type: EXPERIMENTAL
Intervention: PRC-063 (all doses combined)
Number of subjects: 367
Study 34714112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 367
Study 34714112 — intervention group
Group type: EXPERIMENTAL
Intervention: OLE study (PRC-063)
Number of subjects: 367
Study 32432481 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial head arthroplasty
Number of subjects: 152
Study 32432481 — intervention group
Group type: COMPARATOR
Intervention: Radial head fracture fixation
Number of subjects: 152
Study 32244696 — intervention group
Group type: EXPERIMENTAL
Intervention: One meal replacement
Number of subjects: 112
Study 32244696 — intervention group
Group type: EXPERIMENTAL
Intervention: Two meal replacements
Number of subjects: 112
Study 32244696 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 112
Study 36653409 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (150 mg × 3 times/day)
Number of subjects: 20
Study 36653409 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal condition (9-day caffeine followed by 1-day placebo)
Number of subjects: 20
Study 36653409 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 times/day)
Number of subjects: 20
Study 36653409 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 20
Study 34360105 — intervention group
Group type: EXPERIMENTAL
Intervention: Handful
Number of subjects: 120
Study 34360105 — intervention group
Group type: COMPARATOR
Intervention: 30 g serving
Number of subjects: 120
Study 34360105 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual serving
Number of subjects: 120
Study 34360105 — intervention group
Group type: EXPERIMENTAL
Intervention: Large handful
Number of subjects: 120
Study 34360105 — intervention group
Group type: EXPERIMENTAL
Intervention: Small handful
Number of subjects: 120
Study 32481334 — intervention group
Group type: EXPERIMENTAL
Intervention: Fire needle therapy
Number of subjects: 60
Study 32481334 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting with lifestyle advice and education regarding BPH
Number of subjects: 60
Study 34742096 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Number of subjects: 48
Study 34742096 — intervention group
Group type: COMPARATOR
Intervention: Control group (health education sessions)
Number of subjects: 48
Study 33834343 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato cultivars with 3.6 mg kg‐1 Cd
Number of subjects: 3
Study 33834343 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato cultivars with 12 mg kg‐1 Cd
Number of subjects: 3
Study 33834343 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato cultivars with long-term exposure to 12 mg kg‐1 Cd
Number of subjects: 3
Study 35000893 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental formula (EF) with higher protein level of 3.4 g/100 kcal and improved fat blend
Number of subjects: 160
Study 35000893 — intervention group
Group type: COMPARATOR
Intervention: Control formula (CF) with protein level of 2.9 g/100 kcal and standard fat blend
Number of subjects: 160
Study 35000893 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental formula (EF)
Number of subjects: 160
Study 35000893 — intervention group
Group type: COMPARATOR
Intervention: Experimental formula (EF) and Control formula (CF)
Number of subjects: 160
Study 33116455 — intervention group
Group type: EXPERIMENTAL
Intervention: Icenticaftor 300 mg b.i.d.
Number of subjects: 92
Study 33116455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 33734369 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-all strategy (IVF with frozen-thawed blastocyst transfer)
Number of subjects: 205
Study 33734369 — intervention group
Group type: COMPARATOR
Intervention: Conventional strategy (IVF with fresh and frozen-thawed blastocyst transfer)
Number of subjects: 205
Study 35716932 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose colchicine
Number of subjects: 429
Study 35716932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study 33454896 — intervention group
Group type: EXPERIMENTAL
Intervention: CART analysis model
Number of subjects: 151
Study 33454896 — intervention group
Group type: COMPARATOR
Intervention: Conventional Cox model
Number of subjects: 151
Study 32005992 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate iron treatment (ferrous sulfate 2 mg · kg‐1 · d‐1 for 3 months)
Number of subjects: 239
Study 32005992 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed iron treatment (ferrous sulfate 2 mg · kg‐1 · d‐1 for 3 months, starting 28 days after antimalarial treatment)
Number of subjects: 239
Study 32005992 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic community children (comparison group)
Number of subjects: 239
Study 33655794 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated diabetes self-management program using smartphone application
Number of subjects: 68
Study 33713411 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow warnings (YB)
Number of subjects: 1131
Study 33713411 — intervention group
Group type: EXPERIMENTAL
Intervention: White on black warnings (WB)
Number of subjects: 1131